Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 15,098 as of Friday, Aug. 16, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,393 issues advancing vs. 1,555 declining with 92 unchanged. The Health Services industry currently sits down 0.6% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include Edwards Life ( EW), down 2.0%, CareFusion ( CFN), down 1.1%, St Jude Medical ( STJ), down 1.1%, DaVita HealthCare Partners ( DVA), down 1.0% and Waters Corporation ( WAT), down 1.0%. Top gainers within the industry include Parexel International Corporation ( PRXL), up 2.7%, Boston Scientific ( BSX), up 1.6%, Cigna ( CI), up 1.4% and Aetna ( AET), up 0.9%. TheStreet would like to highlight 4 stocks pushing the industry lower today: 4. C.R. Bard ( BCR) is one of the companies pushing the Health Services industry lower today. As of noon trading, C.R. Bard is down $1.89 (-1.7%) to $111.58 on heavy volume. Thus far, 417,193 shares of C.R. Bard exchanged hands as compared to its average daily volume of 541,200 shares. The stock has ranged in price between $111.24-$113.13 after having opened the day at $112.27 as compared to the previous trading day's close of $113.47. C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. C.R. Bard has a market cap of $9.1 billion and is part of the health care sector. Shares are up 16.1% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate C.R. Bard a buy, 1 analyst rates it a sell, and 12 rate it a hold. TheStreet Ratings rates C.R. Bard as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full C.R. Bard Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.